Penicillin V (Penadur) 250 mg twice daily is the recommended oral agent for RHD prophylaxis
For rheumatic heart disease prophylaxis, Penicillin V (phenoxymethylpenicillin) 250 mg twice daily is the guideline-recommended oral regimen, not ampicillin (Sumapen). The American Heart Association explicitly states that Penicillin V at 250 mg twice daily is the recommended oral agent for secondary prevention of rheumatic fever (Class I, LOE B) 1.
Key Evidence Supporting Penicillin V
The 2009 AHA Scientific Statement provides clear guidance that:
- Penicillin V 250 mg twice daily is the standard oral prophylaxis regimen for both children and adults 1
- There are no published data supporting the use of other penicillins (including ampicillin), macrolides, azalides, or cephalosporins for secondary prevention of rheumatic fever 1
- This recommendation carries Class I evidence (should be performed) with Level of Evidence B (data from single randomized trial or nonrandomized studies) 1
Important Caveats About Oral Prophylaxis
Efficacy Considerations
Oral prophylaxis has inherent limitations compared to intramuscular benzathine penicillin G:
- Higher recurrence risk: Even with optimal adherence, oral prophylaxis carries higher risk of rheumatic fever recurrence than intramuscular benzathine penicillin G 1
- Adherence-dependent: Success depends primarily on patient compliance, and most prophylaxis failures occur in nonadherent patients 1
- Recent Cochrane review confirms intramuscular benzathine penicillin is approximately 10 times more effective than oral antibiotics in preventing rheumatic fever recurrence (0.1% vs 1% recurrence rates) 2
Appropriate Patient Selection for Oral Prophylaxis
Oral agents are more appropriate for:
- Lower-risk patients: Those without persistent valvular disease
- Older patients: Late adolescence or young adulthood who have remained attack-free for ≥5 years (Class IIb, LOE C) 1
- Patients who refuse or cannot tolerate intramuscular injections
High-Risk Patients Require Intramuscular Prophylaxis
Intramuscular benzathine penicillin G (1.2 million units every 4 weeks) remains the gold standard (Class I, LOE A) for:
- Patients with rheumatic carditis with or without valvular disease
- Those at high risk for recurrence
- Patients in high-incidence populations 1
Why Not Ampicillin (Sumapen)?
The provided FDA drug label for "Sumapen" 3 describes maropitant citrate, an antiemetic used in veterinary medicine for dogs and cats—this is completely unrelated to rheumatic fever prophylaxis and appears to be an error in the evidence provided. There is no established role for ampicillin in RHD prophylaxis, and guidelines explicitly state no data support other penicillins beyond Penicillin V for oral prophylaxis 1.
Practical Implementation
If oral prophylaxis is chosen:
- Use Penicillin V 250 mg twice daily exclusively
- Provide repeated patient education about adherence importance
- Consider switching to intramuscular prophylaxis if any recurrence occurs
- Monitor closely for breakthrough infections
- Reassess risk-benefit periodically, especially in younger patients or those with valvular disease
The evidence strongly favors intramuscular benzathine penicillin G over any oral regimen when feasible 2, but when oral therapy is necessary, only Penicillin V has guideline support and evidence for RHD prophylaxis.